Official Journal of the Italian Society of Orthopaedics and Traumatology
Table 1 Characteristics of included studies
References | Years | Journal | Intervention | Comparator | Follow-up (months) | Preparation of intervention | Age (years) | Sex (male %) | Dominant side (%) | Duration (months) | VAS (0–10) before treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kazemi et al. [12] | 2010 | AJPMR | AB | Steroid | 2 | Mixed blood with 1 ml of 2 % lidocaine | 47.1 | 18 | 60 | – | 6.60 | VAS, DASH, PPT, adverse effect |
Peerboom et al. [21] | 2010 | AMJ | PRP | Steroid | 12 | The GPS III system | 47.1 | 48 | 63 | – | 6.80 | VAS, DASH, adverse effect |
Thanasas et al. [33] | 2011 | AMJ | PRP | AB | 6 | The GPS III system | 36.3 | 25 | 86 | 5.1 | 6.05 | VAS, adverse effect |
Dojode [6] | 2012 | BJR | AB | Steroid | 6 | Mixed blood with 1 ml of 0.5 % bupivacaine | 42.5 | 42 | 85 | 8.6 | 7.6 | VAS, adverse effect |
Omar et al. [19] | 2012 | Egypt Rheumatologist | PRP | Steroid | 1.5 | Other system | 37.5 | 37 | 60 | 1.8 | 8.40 | VAS, DASH |
Singh et al. [26] | 2013 | J Health Allied Sci | AB | Steroid | 3 | Mixed blood with 1 ml of 2 % lidocaine | 34.1 | 47 | 57 | 18.1 | – | PRTEE |
Krogh et al. [14] | 2013 | AMJ | PRP | Steroid | 3 | The Recover GPS II system | 45.8 | 50 | 80 | – | 5.55 | PRTEE, adverse effect |
Creaney et al. [5] | 2014 | BJSM | PRP | AB | 6 | Other system | 50.1 | 56.5 | – | – | – | PRTEE |
Raeissadat et al. [23] | 2014 | BMC Sports Science | PRP | AB | 12 | The Rooyagen kit | 43.5 | 23 | 67 | – | 6.95 | VAS, PPT |
Raeissadat et al. [24] | 2014 | Pain Research and Treatment | PRP | AB | 2 | The Rooyagen kit | 46.3 | 40 | 65 | – | 7.00 | VAS, PPT |